GPRC5A/RAI3 Antibody - BSA Free

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743]

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743] - Staining of human lung shows moderate membranous positivity in pneumocytes.

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743]

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743] - Staining of human skeletal muscle shows no positivity in myocytes as expected.

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743]

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743] - Staining of human small intestine shows moderate positivity in apical membrane in glandular cells.

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743]

Immunohistochemistry-Paraffin: GPRC5A/RAI3 Antibody [NBP1-89743] - Staining of human urinary bladder shows moderate membranous positivity in urothelial cells.

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743]

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] - (J) RAI3 has a conspicuously low expression in BxPc3 and PaCaDD165 in comparison to the other cell lines in the group. (n = 3). (PLoS One. 2017; 12 (1): e0170390. Published online 2017 Jan 23.)

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743]

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] - Wester Blot: Pancreatic cell lines, where NC1 and NC2 represent negative controls.

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] -

Western Blot analysis of different pathways were tested for alteration in knock-down with GPRC5A siRNA in comparison to negative control.Phosphorylation of STAT3 at Tyr705 is reduced in knock-down of all three cell lines, whereas Phospho-ERK is not changed significantly (see S2 Fig for original Western blot images). (n = 3).

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] -

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] - GPRC5a expression levels in normal pancreas & PaCa (PAAD) tissue & cell lines. (A,B) The data-mining analysis showed that GPRC5a was significantly upregulated in PaCa (PAAD) samples with an association of increased expression in higher malignant tumor stages (p < 0.05). (C,D) The Western blot & qPCR results showed that the basic protein-level expression of GPRC5a in PaCa cell lines was higher than that in the HPDEE6E7 pancreas cell line. (E) Immunofluorescence assay showed upregulated expression of GPRC5a in PaCa cell lines (200×). The error bars were from multiple samples (n) measurement results (A,B) or three experimental measurements (C,D). * p-value < 0.05. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29949874), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] -

Western Blot: GPRC5A/RAI3 Antibody [NBP1-89743] - Influence of GPRC5a knockout on the proliferation & migration ability in MIA PaCa-2 & TB32047 cells. (A–D) Western blot & sequencing results showing the GPRC5a knocked out in MIA PaCa-2-KO1/2 & TB32047-KO1/2 (Red highlight area means the different part in comparison of sequencing sequence). (E,F): The knockout of GPRC5a inhibited the proliferation ability of MIA PaCa-2 & TB32047 cells. (G,H) GPRC5a knockout inhibited the migration ability of MIA PaCa-2 (G) & TB32047 cells (H). * p-value < 0.05. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29949874), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPRC5A/RAI3 Antibody - BSA Free [NBP1-89743]

Analysis in human cell lines A-431 and U-251MG using Anti-GPRC5A antibody. Corresponding GPRC5A RNA-seq data are presented for the same cell lines. Loading control: Anti-HSP90B1.